Matches in Nanopublications for { ?s ?p "[Association with other oncogene expression (TAL1, HOXAs, or TLX3/HOX11L2), NOTCH1 activating mutations, and/or CDKN2A/p16/ARF deletion, showed that cyclin D2 dysregulation could contribute to multi-event oncogenesis in various T-ALL groups.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 13 of
13
with 100 items per page.
- assertion description "[Association with other oncogene expression (TAL1, HOXAs, or TLX3/HOX11L2), NOTCH1 activating mutations, and/or CDKN2A/p16/ARF deletion, showed that cyclin D2 dysregulation could contribute to multi-event oncogenesis in various T-ALL groups.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP722571.RASI4mvpXDpmYmWOL1Jx2i-elPtwGlq2U1wjnvP7_WDiE130_assertion description "[Association with other oncogene expression (TAL1, HOXAs, or TLX3/HOX11L2), NOTCH1 activating mutations, and/or CDKN2A/p16/ARF deletion, showed that cyclin D2 dysregulation could contribute to multi-event oncogenesis in various T-ALL groups.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP722571.RASI4mvpXDpmYmWOL1Jx2i-elPtwGlq2U1wjnvP7_WDiE130_provenance.
- assertion description "[Association with other oncogene expression (TAL1, HOXAs, or TLX3/HOX11L2), NOTCH1 activating mutations, and/or CDKN2A/p16/ARF deletion, showed that cyclin D2 dysregulation could contribute to multi-event oncogenesis in various T-ALL groups.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Association with other oncogene expression (TAL1, HOXAs, or TLX3/HOX11L2), NOTCH1 activating mutations, and/or CDKN2A/p16/ARF deletion, showed that cyclin D2 dysregulation could contribute to multi-event oncogenesis in various T-ALL groups.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Association with other oncogene expression (TAL1, HOXAs, or TLX3/HOX11L2), NOTCH1 activating mutations, and/or CDKN2A/p16/ARF deletion, showed that cyclin D2 dysregulation could contribute to multi-event oncogenesis in various T-ALL groups.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Association with other oncogene expression (TAL1, HOXAs, or TLX3/HOX11L2), NOTCH1 activating mutations, and/or CDKN2A/p16/ARF deletion, showed that cyclin D2 dysregulation could contribute to multi-event oncogenesis in various T-ALL groups.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP288029.RAqriRFHIVVSCkgB7OlJP618o7qnhksRoIXb44ThIdzKw130_assertion description "[Association with other oncogene expression (TAL1, HOXAs, or TLX3/HOX11L2), NOTCH1 activating mutations, and/or CDKN2A/p16/ARF deletion, showed that cyclin D2 dysregulation could contribute to multi-event oncogenesis in various T-ALL groups.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP288029.RAqriRFHIVVSCkgB7OlJP618o7qnhksRoIXb44ThIdzKw130_provenance.
- NP521027.RADnkMPqXwe_gGh14vodr3j-2KvNhUtr43w4yAB2R5-Sg130_assertion description "[Association with other oncogene expression (TAL1, HOXAs, or TLX3/HOX11L2), NOTCH1 activating mutations, and/or CDKN2A/p16/ARF deletion, showed that cyclin D2 dysregulation could contribute to multi-event oncogenesis in various T-ALL groups.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP521027.RADnkMPqXwe_gGh14vodr3j-2KvNhUtr43w4yAB2R5-Sg130_provenance.
- NP521032.RAVvx7k3w1F4c76cjXCAjlV9XIthiUlI5ykEI2ntxFDoM130_assertion description "[Association with other oncogene expression (TAL1, HOXAs, or TLX3/HOX11L2), NOTCH1 activating mutations, and/or CDKN2A/p16/ARF deletion, showed that cyclin D2 dysregulation could contribute to multi-event oncogenesis in various T-ALL groups.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP521032.RAVvx7k3w1F4c76cjXCAjlV9XIthiUlI5ykEI2ntxFDoM130_provenance.
- NP521029.RAofPY-S1zbc1uepkKqGPg0sX5yk_niA0w-WSxz0XQplA130_assertion description "[Association with other oncogene expression (TAL1, HOXAs, or TLX3/HOX11L2), NOTCH1 activating mutations, and/or CDKN2A/p16/ARF deletion, showed that cyclin D2 dysregulation could contribute to multi-event oncogenesis in various T-ALL groups.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP521029.RAofPY-S1zbc1uepkKqGPg0sX5yk_niA0w-WSxz0XQplA130_provenance.
- NP895842.RAGNKKGuwDoOB6fcxCXdsQfcfiUJ8zgMOjUAC7smHBfA0130_assertion description "[Association with other oncogene expression (TAL1, HOXAs, or TLX3/HOX11L2), NOTCH1 activating mutations, and/or CDKN2A/p16/ARF deletion, showed that cyclin D2 dysregulation could contribute to multi-event oncogenesis in various T-ALL groups.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP895842.RAGNKKGuwDoOB6fcxCXdsQfcfiUJ8zgMOjUAC7smHBfA0130_provenance.
- NP521028.RAwVvSQKqhelbBu6EN4JW0k9Cf1J1DaklT6MpxWcQXkYs130_assertion description "[Association with other oncogene expression (TAL1, HOXAs, or TLX3/HOX11L2), NOTCH1 activating mutations, and/or CDKN2A/p16/ARF deletion, showed that cyclin D2 dysregulation could contribute to multi-event oncogenesis in various T-ALL groups.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP521028.RAwVvSQKqhelbBu6EN4JW0k9Cf1J1DaklT6MpxWcQXkYs130_provenance.
- NP521031.RA9Xn5gW8_rtAhARepJ9kDrfcr1vZs8BbCpXFf1TyeA1Y130_assertion description "[Association with other oncogene expression (TAL1, HOXAs, or TLX3/HOX11L2), NOTCH1 activating mutations, and/or CDKN2A/p16/ARF deletion, showed that cyclin D2 dysregulation could contribute to multi-event oncogenesis in various T-ALL groups.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP521031.RA9Xn5gW8_rtAhARepJ9kDrfcr1vZs8BbCpXFf1TyeA1Y130_provenance.